Kluwer Patent Blog

Eli Lilly v. HGS (Court of Appeal), Court of Appeal Civil Division (Court of Appeal Civil Division), 09 February 2010

Sam Tuxford · Tuesday, February 9th, 2010 · Landmark European Patent Cases

The Court of Appeal upheld the High Court's judgment that HGS' patent relating to a new protein called Neutrokine-? was invalid for lack of industrial application. The Court of Appeal agreed with the High Court's determination that uses for Neutrokine-? disclosed in the patent were not plausible at the time the patent was filed as it would have been necessary to perform a research program to ascertain which, if any, of the proposed uses were real. The Court of Appeal reached a different decision to the Technical Board of Appeal of the EPO who found HGS' patent to be valid. The Court of Appeal explained that this was in part due to new evidence which had been submitted in the EPO appeal which could not be introduced into the UK appeal.

The full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?


Learn how **Kluwer IP Law** can support you.

1

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law. The master resource for Intellectual Property rights and registration.





2022 SURVEY REPORT The Wolters Kluwer Future Ready Lawyer Leading change

This entry was posted on Tuesday, February 9th, 2010 at 8:26 am and is filed under Biologics, Case Law, Industrial application, United Kingdom

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.